ExploreWatchlistsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Research & development

LIGAND PHARMACEUTICALS INC (LGND)

Market cap
$4.7B
P/E ratio
38.2x
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202581+278.91%
Dec 31, 202421-12.68%
Dec 31, 202325-32.00%
Dec 31, 202236-47.72%
Dec 31, 202169+16.20%
Dec 31, 202059+6.23%
Dec 31, 201956+100.65%
Dec 31, 201828+3.63%
Dec 31, 201727+26.70%
Dec 31, 201621+58.60%
Dec 31, 201513+10.38%
Dec 31, 201412+30.71%
Dec 31, 20139-14.05%
Dec 31, 201211+4.85%
Dec 31, 201110

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat